Quantitative susceptibility mapping is more sensitive and specific than phase imaging in detecting chronic active multiple sclerosis lesion rims: pathological validation

Citations Over TimeTop 20% of 2024 papers

Abstract

Quantitative susceptibility mapping and phase imaging are used to identify multiple sclerosis lesions with paramagnetic rims that slowly expand over time and are associated with earlier progression to disability, decreased brain volume and increased frequency of clinical relapse. However, the presence of iron-laden microglia/macrophages at the lesion rim and demyelination within the lesion both contribute to phase and quantitative susceptibility mapping images. Therefore, simultaneous pathological validation is needed to assess accuracies in identifying iron-positive lesions. MRI was performed on 15 multiple sclerosis brain slabs; 32 lesions of interest were processed for myelin, iron and microglial markers. Three experienced readers classified lesions as rim positive or negative on quantitative susceptibility mapping and phase; these classifications were compared with Perls' stain as the gold standard. All 10 of the quantitative susceptibility mapping-positive lesions had iron-positive rims on histology. Of the 16 phase-positive lesions, only 10 had iron-positive rims on histology. Using Perls' stain as the ground truth, the positive predictive value was 100% for quantitative susceptibility mapping and 63% for phase; the negative predictive value was 95% for quantitative susceptibility mapping and 94% for phase. Post-mortem imaging results demonstrate that quantitative susceptibility mapping is a more reliable indicator of an iron-positive rim compared with phase imaging.

Related Papers

• → Real world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centers(2025)4 cited
• → Multiple Sclerosis-Associated Virus-Related pol Sequences Found Both in Multiple Sclerosis and Healthy Donors are More Frequently Expressed in Multiple Sclerosis Patients(2003)6 cited
• → Relation of fingolimod treatment to disability in multiple sclerosis(2017)
• → Astrocytes in the pathogenesis of multiple sclerosis(2021)
• → Role of Plasma MicroRNAs 145 and 484 in Diagnosis of Multiple Sclerosis, Disease Activity and the Transition from Relapsing Remitting Multiple Sclerosis to Secondary Progressive Multiple Sclerosis(2023)